When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Why This Beaten-Down Stock Is a Buy in 2025 and Beyond - AOL

   www.aol.com/why-beaten-down-stock-buy-134500720.html

   Merck's Keytruda generates over $20 billion in sales annually, an incredibly rare feat for a medicine. ... It shouldn't win more than a couple (or so) of indications before Keytruda's patent cliff ...

3. Merck posts better-than-expected results on Keytruda ... - AOL

   www.aol.com/news/merck-posts-better-expected...

   Keytruda sales rose 21% to $6.6 billion as the company was able to increase use of the drug in earlier stage cancers, topping analyst forecasts of $6.5 billion. For the full year, Keytruda ...

4. Pembrolizumab - Wikipedia

   en.wikipedia.org/wiki/Pembrolizumab

   Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...

5. Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes - AOL

   www.aol.com/news/merck-banks-keytruda-pipeline...

   Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.

6. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...

7. Merck & Co. - Wikipedia

   en.wikipedia.org/wiki/Merck_&_Co.

   Gardasil 9 in French packaging (showing the MSD branding) The company develops medicines, vaccines, biologic therapies and animal health products. In 2020, the company had 6 blockbuster drugs or products, each with over $1 billion in revenue: Keytruda (pembrolizumab), a humanized antibody used in cancer immunotherapy that had $14.3 billion in 2020 revenue; Januvia (sitagliptin), an anti ...